SAREPTA THERAPEUTICS, INC. Operating Lease, Payments
SAREPTA THERAPEUTICS, INC. (SRPT) reported Operating Lease, Payments of $35.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2019-12-31 was $2.81M.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2019-09-30 was $2.79M.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2019-06-30 was $2.44M.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for the quarter ending 2019-03-31 was $2.38M.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $35.46M, a 6.72% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $33.23M, a 53.76% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $21.61M, a 3.99% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. operating lease, payments for fiscal 2022 was $20.78M, a 15.01% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $35.46M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $33.23M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $21.61M 10-K · filed 2025-02-28 | |||
| 2022-12-31 | $20.78M 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $24.45M 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $19.34M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.60M derived: sum of 2 quarters · filed 2020-02-26 | $8.04M derived: sum of 3 quarters · filed 2020-02-26 | $10.42M 10-K · filed 2020-02-26 |
| 2019-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $5.23M derived: sum of 2 quarters · filed 2019-11-07 | $7.61M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $4.82M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $2.38M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |